Literature DB >> 22915767

Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.

Eduard Jirkovsky1, Olga Popelová, Pavla Kriváková-Stanková, Anna Vávrová, Milos Hroch, Pavlína Hasková, Eva Brcáková-Dolezelová, Stanislav Micuda, Michaela Adamcová, Tomás Simůnek, Zuzana Cervinková, Vladimír Gersl, Martin Sterba.   

Abstract

Anthracycline anticancer drugs (e.g., doxorubicin or daunorubicin) can induce chronic cardiotoxicity and heart failure (HF), both of which are believed to be based on oxidative injury and mitochondrial damage. In this study, molecular and functional changes induced by chronic anthracycline treatment with progression into HF in post-treatment follow-up were analyzed with special emphasis on nuclear factor erythroid 2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) pathways. Chronic cardiotoxicity was induced in rabbits with daunorubicin (3 mg/kg, weekly for 10 weeks), and the animals were followed for another 10 weeks. Echocardiography revealed a significant drop in left ventricular (LV) systolic function during the treatment with marked progression to LV dilation and congestive HF in the follow-up. Although daunorubicin-induced LV lipoperoxidation was found, it was only loosely associated with cardiac performance. Furthermore, although LV oxidized glutathione content was increased, the oxidized-to-reduced glutathione ratio itself remained unchanged. Neither Nrf2, the master regulator of antioxidant response, nor the majority of its target genes showed up-regulation in the study. However, down-regulation of manganese superoxide dismutase and NAD(P)H dehydrogenase [quinone] 1 were observed together with heme oxygenase 1 up-regulation. Although marked perturbations in mitochondrial functions were found, no induction of PGC1α-controlled mitochondrial biogenesis pathway was revealed. Instead, especially in the post-treatment period, an impaired regulation of this pathway was observed along with down-regulation of the expression of mitochondrial genes. These results imply that global oxidative stress need not be a factor responsible for the development of anthracycline-induced HF, whereas suppression of mitochondrial biogenesis might be involved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915767     DOI: 10.1124/jpet.112.198358

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Sulforaphane protects the heart from doxorubicin-induced toxicity.

Authors:  Preeti Singh; Rajendra Sharma; Kevin McElhanon; Charles D Allen; Judit K Megyesi; Helen Beneš; Sharda P Singh
Journal:  Free Radic Biol Med       Date:  2015-05-27       Impact factor: 7.376

2.  Chronic intermittent hypoxia affects the cytosolic phospholipase A2α/cyclooxygenase 2 pathway via β2-adrenoceptor-mediated ERK/p38 stimulation.

Authors:  Petra Micova; Klara Hahnova; Marketa Hlavackova; Barbara Elsnicova; Anna Chytilova; Kristyna Holzerova; Jitka Zurmanova; Jan Neckar; Frantisek Kolar; Olga Novakova; Jiri Novotny
Journal:  Mol Cell Biochem       Date:  2016-09-30       Impact factor: 3.396

3.  Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment.

Authors:  Qian Guo; Jiabin Guo; Rong Yang; Hui Peng; Jun Zhao; Li Li; Shuangqing Peng
Journal:  Oxid Med Cell Longev       Date:  2015-05-14       Impact factor: 6.543

4.  Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment.

Authors:  Maryline Moulin; Audrey Solgadi; Vladimir Veksler; Anne Garnier; Renée Ventura-Clapier; Pierre Chaminade
Journal:  Biol Sex Differ       Date:  2015-10-15       Impact factor: 5.027

Review 5.  NRF2 in Cardiovascular Diseases: a Ray of Hope!

Authors:  Ruju Vashi; Bhoomika M Patel
Journal:  J Cardiovasc Transl Res       Date:  2020-11-25       Impact factor: 4.132

6.  Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies.

Authors:  Sheng-Miauh Huang; Li-Yin Chien; Cheng-Jeng Tai; Ling-Ming Tseng; Ping-Ho Chen; Chen-Jei Tai
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-21       Impact factor: 2.629

7.  Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor.

Authors:  Mayel Gharanei; Afthab Hussain; Omar Janneh; Helen Maddock
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

Review 8.  The role of Nrf2-mediated pathway in cardiac remodeling and heart failure.

Authors:  Shanshan Zhou; Wanqing Sun; Zhiguo Zhang; Yang Zheng
Journal:  Oxid Med Cell Longev       Date:  2014-07-01       Impact factor: 6.543

9.  Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.

Authors:  Robin Chung; Angshuman Maulik; Ashraf Hamarneh; Daniel Hochhauser; Derek J Hausenloy; J Malcolm Walker; Derek M Yellon
Journal:  Clin Cardiol       Date:  2016-01-25       Impact factor: 2.882

10.  Cardiotoxicity of anthracycline therapy: current perspectives.

Authors:  Mihaela Valcovici; Florina Andrica; Corina Serban; Simona Dragan
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.